title: Mayo v. Prometheus: A Year Later.
abstract: Last year's U.S. Supreme Court decision in Mayo v. Prometheus regarding the patent eligibility of diagnostic method claims will probably have the most profound lasting effect of any recent court decision on the biopharmaceutical industry. The Mayo decision changed the evaluation of patent eligibility of a method claim under 35 U.S.C. § 101. The new evaluation is a more difficult standard to clear and needs to be considered prior to filing a patent application.
authors.affiliation: Barnes & Thornburg LLP , Minneapolis, Minnesota 55447, United States.
authors.forename: Brian R
authors.initials: BR
authors.lastname: Dorn